Tuesday, 29 September 2026Updated 8m ago
← Top stories
Broker call▲ Bullish for Sun Pharma

Expanding innovative portfolio may drive gains for Sun Pharma stock

1 source · first seen 17:56 29 Sept · updated 17:56 29 Sept

The brief

Written from 1 report · check the source before you trade
  • Lerodalcibep licensing, US portfolio growth and tariff relief are cited as potential stock drivers
  • A proposed Organon acquisition could broaden Sun Pharma’s global reach
  • Potential growth and acquisition catalysts matter to Sun Pharma shareholders

Tags on this story

Pick a tag to see all its stories
Sun Pharma₹1,865.00 · 8 todayLerodalcibep3 todayOrganon2 todayPharma and healthcare46 today

Linked by the tag Organon

2 stories this week
  1. 29 SeptSun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: ReportFunding and debt · 1 source · Sun Pharma plans a ₹10,000 crore bond sale to refinance its Organon deal
All Organon stories →
Part of a developing story2 updates over 2 days

Sun Pharma’s Lerodalcibep licensing

Sun Pharma secured rights to commercialise and manufacture Lerodalcibep worldwide, excluding the US and China; the once-monthly PCSK9 inhibitor treats adults. Analysts cited the licensing deal, US portfolio growth and tariff relief as potential stock drivers.

Tuesday, 29 September

  1. You are here
    Expanding innovative portfolio may drive gains for Sun Pharma stock

Monday, 28 September

  1. 8 sources
    Sun Pharma secures rights to commercialise Lerodalcibep outside the US and China

Follow the full storyline →

Read the reports

1 report · earliest 17:56
Business StandardExpanding innovative portfolio may drive gains for Sun Pharma stock17:56